The Company was incorporated on 16th April, 1990 under the Act as a Private Limited Company under the name of CAPLIN POINT LABORATORIES PRIVATE LIMITED. The name of the Company was changed to CAPLIN POINT LABORATORIES LIMITED effective 23rd April 1993. The Company has adopted a new set of Articles on 12th March, 1993 as applicable to public limited companies.
The Company was incorporated as an extension of a pharmaceutical manufacturing unit started by M/s Triwin Pharmaceuticals, the first pharmaceutical venture started by Mr. P C Partheeban (presently the Managing Director), Mr. T Palanisamy and Mr. S Karunakaran in the year 1987 as a partnership firm. In the year 1990, the Company was
incorporated by the partners of the aforesaid firm alongwith Mr. B A Ahmed. Soon thereafter, Mr. S Jayaraman joined the Board to take charge of production.
Recently, the Board has been recast with all Directors except Mr.P.C.Partheeban making room for broadbasing the Board. The resigning Directors have taken positions as Senior level Managers in the Company.
M/s Triwin Pharmaceuticals was engaged in the business of manufacture of Tablets, Liquid orals and Capsules (Non-Antibiotic) and Import Sales of family planning and certain life saving drugs. The said firm also started the Export of manufactured formulations in the year 1992-93.
Even after the incorporation of the Company, the firm continued its manufacturing, sales and export of Tablets, Liquid orals and Capsules (Non-Antibiotic) and business of import sales while the Company started the manufacture of Ointments, Oral Powders and Capsules (Antibiotic).
The said firm has since been taken over by the Company with effect from 1st September, 1993 with the objective of consolidation of the business of the Company into a single larger entity for setting up the Project envisaged. All the assets and liabilities of the firm were taken over at book values as at 31st August 1993. The Company's turnover in
future shall comprise of the sales generated from the manufacturing faculties of the erstwhile firm also. Salient terms of the takeover Agreement executed by the Company with M/s. Triwin Pharmacuticals ('Triwin') are as follows.
a. Transfer and vesting of assets and liabilities of Triwin in the Company
All the assets and liabilities of Triwin including its factory located at No. 44, Kamakoti Nagar Annexe,Valasaravakkam, Madras 600 087, on going business basis are transferred at book values as on 31st August 1993.
b. Net consideration for the transfer of assets and liabilities
Consideration payable by the Company shall be the net worth of Triwin (excluding good will) estimated at Rs.31,62,000 on the basis of its audited accounts as at 31st August 1993.
c. Continuance of Business
In the post-transfer stage, the Company to continue to do the business then carried on by Triwin (including the manufacturing operation) and Triwin shall suspend all the production/sales activities hitherto carried on by them.
d. Discharge of Purchase consideration
The Company to issue at par its Shares credited as fully paid-up to the partners of Triwin for an aggregate nominal value of Rs. 31,62,000 (Rupees Thirty One lacs Sixty Two Thousand only) in the proportion of amounts lying to the credit of the respective capital/current accounts as on 31st August 1993.
2010
-Caplin Point Laboratories Ltd has recommended a final dividend of Re. 1/- per share (10%)
2011
-Caplin Point Laboratories Ltd has Recommended a final Dividend of Re. 1.50 per share (15%)
-Mr. Vivek Siddharth has been appointed as the Chief Operating Officer of the Company
2012
-Caplin Point Laboratories Ltd has recommended dividend a final dividend of Rs. 2/- per share (20%)
-Mr. D. P. Mishra has been appointed as a Whole Time Director of the Company
2013
-Mr. Mohanraj has been appointed as the Vice President - Finance and Company Secretary of the company.
2014
-Caplin has commenced its additional line of Production in the area of Suppositories which is unique in its feature which very few Pharma Companies have.
-Caplin Point Lab gets listing on Forbes Asia and rsquo;s ‘200 Best Billion and rsquo; 2014.
2015
-Caplin Point Lab - Caplin Point gets EU GMP approval for Sterile Injectable Site
-Caplin Point Lab - Caplin Point gets Brazil's Anvisa approval for Sterile Injectable Site
2016
-Caplin Point Lab - US FDA inspection completed at Caplin Point's Injectable site.
2017
-Caplin Point Laboratories received approval from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product developed for Cycle Pharmaceuticals.
-Caplin Point gets USFDA nod for Ketorolac Tromethamine Injection.
2018
-USFDA completes inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu.
2019
-Caplin Point Laboratories partners with Baxter Corporation for injectable portfolio.
-USFDA completes inspection at Caplin Steriles Injectable site.
-Caplin Steriles gets USFDA nod for hemorrhage prevention drug.
-Caplin Point Labs gets EIR from USFDA for injectable facility.
2020
-Caplin Point Laboratories Chairman C C Paarthipan said the company has partnered with Xellia which has a long standing track record of commercial success in the US for injectable products.
-Caplin Point Laboratories received the final approval from the US drug regulator for its Abbreviated New Drug Application (ANDA) Phenylephrine Hydrochloride injection.
-Caplin Point Laboratories Ltd -Caplin Steriles Gets USFDA Approval For Verapamil Hydrochloride Injection USP
2021
-Caplin Point arm inks strategic partnership with Canada's JAMP Pharma Group.
-Caplin Point Laboratories arm gets USFDA nod for Neostigmine Methylsulfate Injection.
2023
- Lifetime Achievement Award 2023-Business
- Forbes Asia Best Under Billion Award 2023
|